cd20 antigens

Summary

Summary: Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.

Top Publications

  1. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
  2. ncbi The biology of CD20 and its potential as a target for mAb therapy
    Mark S Cragg
    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University, Southampton General Hospital, Southampton, UK
    Curr Dir Autoimmun 8:140-74. 2005
  3. ncbi Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma 5:98-101. 2004
  4. ncbi Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:67-74. 2002
  5. ncbi Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
    P McLaughlin
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2825-33. 1998
  6. ncbi Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
    B Bellosillo
    Hematopathology Unit, Department of Hematology, Institute of Hematology and Oncology, , Barcelona, Spain
    Blood 98:2771-7. 2001
  7. ncbi Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Jonathan C W Edwards
    University College London, London, United Kingdom
    N Engl J Med 350:2572-81. 2004
  8. pmc Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis
    E Janas
    Rheumatoid Arthritis Biology, RI CEDD, Stevenage, UK
    Clin Exp Immunol 139:439-46. 2005
  9. pmc Systemic and cell type-specific gene expression patterns in scleroderma skin
    Michael L Whitfield
    Department of Dermatology, University of California San Francisco, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 100:12319-24. 2003
  10. ncbi Japanese experience of ABO-incompatible living kidney transplantation
    Kazunari Tanabe
    Department of Urology, Graduate School of Medicine, Tokyo Women s Medical University, Tokyo, Japan
    Transplantation 84:S4-7. 2007

Detail Information

Publications217 found, 100 shown here

  1. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
    ..This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas...
  2. ncbi The biology of CD20 and its potential as a target for mAb therapy
    Mark S Cragg
    Tenovus Research Laboratory, Cancer Sciences Division, Southampton University, Southampton General Hospital, Southampton, UK
    Curr Dir Autoimmun 8:140-74. 2005
    ....
  3. ncbi Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma 5:98-101. 2004
    ..These results confirm that 90Y ibritumomab tiuxetan produces high response rates and durable remissions in patients with previously treated low-grade, follicular, and transformed NHL...
  4. ncbi Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:67-74. 2002
    ..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
  5. ncbi Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
    P McLaughlin
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2825-33. 1998
    ..It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies...
  6. ncbi Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
    B Bellosillo
    Hematopathology Unit, Department of Hematology, Institute of Hematology and Oncology, , Barcelona, Spain
    Blood 98:2771-7. 2001
    ..In conclusion, the results of the present study suggest that CD20, CD59, and complement have a role in the in vitro cytotoxic effect of rituximab, which is mediated by a caspase-independent process that involves ROS generation...
  7. ncbi Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Jonathan C W Edwards
    University College London, London, United Kingdom
    N Engl J Med 350:2572-81. 2004
    ..To confirm these observations, we conducted a randomized, double-blind, controlled study...
  8. pmc Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis
    E Janas
    Rheumatoid Arthritis Biology, RI CEDD, Stevenage, UK
    Clin Exp Immunol 139:439-46. 2005
    ..These data show, for the first time, that Rituxan-induced translocation of CD20 to lipid rafts is important for increased intracellular Ca(2+) levels and downstream apoptotic signalling...
  9. pmc Systemic and cell type-specific gene expression patterns in scleroderma skin
    Michael L Whitfield
    Department of Dermatology, University of California San Francisco, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 100:12319-24. 2003
    ..These results provide evidence that scleroderma has systemic manifestations that affect multiple cell types and suggests genes that could be used as potential markers for the disease...
  10. ncbi Japanese experience of ABO-incompatible living kidney transplantation
    Kazunari Tanabe
    Department of Urology, Graduate School of Medicine, Tokyo Women s Medical University, Tokyo, Japan
    Transplantation 84:S4-7. 2007
    ..In addition, rituximab as an alternative to splenectomy is definitely an effective regimen for successful ABO-ILKT...
  11. pmc Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking
    Tammy L Unruh
    Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada
    Immunology 116:223-32. 2005
    ..Taken together, the data demonstrate that CD20 hypercrosslinking via rituximab activates SFKs and downstream signalling events by clustering membrane rafts in which antibody-bound CD20 is localized in a high-affinity configuration...
  12. ncbi Effective B cell depletion with rituximab in the treatment of autoimmune diseases
    Christian Kneitz
    Medizinische Poliklinik der Universität Würzburg, Germany
    Immunobiology 206:519-27. 2002
    ..Further studies are needed to assess the clinical benefit of B cell depletion in the treatment of autoimmune diseases...
  13. ncbi Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA
    Clin Cancer Res 9:5866-73. 2003
    ..The purpose of this work was to study the effect(s) of neutrophils on the in vivo antitumor activity of rituximab...
  14. ncbi Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis
    C C Reparon-Schuijt
    Leiden University Medical Center, The Netherlands
    Arthritis Rheum 44:2029-37. 2001
    ..The capacity of these cells to respond to activation by the production of Ig supports the notion that these cells might serve as Ig-producing effector cells and, as such, play a role in the pathophysiology of RA...
  15. ncbi Store-operated cation entry mediated by CD20 in membrane rafts
    Haidong Li
    Immunology Research Group, Department of Biochemistry and Molecular Biology, University of Calgary Health Sciences Center, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    J Biol Chem 278:42427-34. 2003
    ..This is the first evidence that raft-associated CD20 constitutes a component of a SOC entry pathway activated by the B cell receptor...
  16. ncbi Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis
    J M Foran
    Imperial Cancer Research Fund Medical Oncology Unit, St Bartholomew s Hospital, London, UK
    Br J Haematol 114:881-3. 2001
    ..Frank loss of CD20 was not seen in 25 post-treatment lymph node biopsies. Immunophenotyping is therefore an important adjunct in the diagnosis of BM infiltration following rituximab...
  17. ncbi Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
    Naoko Yamane-Ohnuki
    Tokyo Research Laboratories, Kyowa Hakko Kogyo Co, Ltd, 3 6 6 Asahi machi, Machida shi, Tokyo 194 8533, Japan
    Biotechnol Bioeng 87:614-22. 2004
    ..Our results demonstrate that FUT8(-/-) cells are ideal host cell lines to stably produce completely defucosylated high-ADCC antibodies with fixed quality and efficacy for therapeutic use...
  18. ncbi Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
    Russell Schilder
    Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911 2412, USA
    Cancer Biother Radiopharm 19:478-81. 2004
    ..Toxicities were primarily hematologic and reversible. No additional long-term adverse events have been observed in the follow-up period, and treatment did not preclude subsequent lymphoma therapies...
  19. ncbi Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Clin Lymphoma 5:S22-6. 2004
    ..This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation...
  20. ncbi CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins
    Maria J Polyak
    Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada
    J Biol Chem 283:18545-52. 2008
    ....
  21. pmc The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
    Junji Uchida
    Department of Immunology, Box 3010, Room 353 Jones Building, Research Drive, Duke University Medical Center, Durham, NC 27710, USA
    J Exp Med 199:1659-69. 2004
    ..That the innate monocyte network depletes B cells through FcgammaR-dependent pathways during anti-CD20 immunotherapy has important clinical implications for anti-CD20 and other antibody-based therapies...
  22. ncbi Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts
    Mitchell R Smith
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Mol Cancer Ther 3:1693-9. 2004
    ..This merits investigation in clinical trials...
  23. ncbi Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 123:850-7. 2003
    ..The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study...
  24. ncbi Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    S Sacchi
    Department of Internal Medicine, Oncology and Radiology, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41100 Modena, Italy
    Crit Rev Oncol Hematol 37:13-25. 2001
    ..The aim of future studies should be to develop new strategies that will hopefully produce the most effective Rituximab-based regimens in order to find the Rituximab key position in the treatment of B-malignancies..
  25. ncbi Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
    Donald M Arnold
    McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada
    Ann Intern Med 146:25-33. 2007
    ..Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP)...
  26. ncbi The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
    Jessica L Teeling
    Genmab, Utrecht, The Netherlands
    J Immunol 177:362-71. 2006
    ..We conclude that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis...
  27. pmc Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes
    J K Bubien
    Department of Medicine, University of Alabama, Birmingham 35294
    J Cell Biol 121:1121-32. 1993
    ....
  28. pmc Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice
    Jean David Bouaziz
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 104:20878-83. 2007
    ..These results provide direct evidence that B cells contribute to T cell activation and expansion in vivo and offer insights into the mechanism of action for B cell depletion therapy in the treatment of autoimmunity...
  29. ncbi Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody
    Henry N Wagner
    School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205, USA
    J Nucl Med 43:267-72. 2002
    ..Understanding the unique properties of this novel radioimmunoconjugate will facilitate its safe and effective use...
  30. ncbi Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts
    Ryan J Petrie
    Department of Biochemistry and Molecular Biology, Immunology Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
    J Immunol 169:2886-91. 2002
    ..Activation-dependent dissociation of the BCR from CD20 occurs before receptor endocytosis and appears to require in part the integrity of lipid rafts...
  31. pmc Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
    A Kavanaugh
    University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, 9500 Gilman Drive, Mail Code 0943, La Jolla, CA 92093 0943, USA
    Ann Rheum Dis 67:402-8. 2008
    ..Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fully defined...
  32. ncbi Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure
    Maria J Polyak
    Department of Biochemistry, Immunology Research Group, University of Calgary, Calgary, Alberta, Canada
    Blood 99:3256-62. 2002
    ....
  33. ncbi Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers
    Daniel S Warren
    The Department of Surgery, The Johns Hopkins University School of Medicine, Balitmore, Maryland, USA
    Am J Transplant 4:561-8. 2004
    ..The ability to cross these two barriers simultaneously is clinically important as sensitized patients have often exhausted their blood type compatible living donors during previous transplants...
  34. ncbi Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells
    Isabelle Semac
    Department of Pathology, Faculty of Medicine, Centre Medical Universitaire, 1211 Geneva 4, Switzerland
    Cancer Res 63:534-40. 2003
    ..By redistributing CD20 to rafts, RTX modifies their stability and organization and modulates the associated signaling pathways and C' defense capacity...
  35. ncbi Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Mitchell R Smith
    Lymphoma Service, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Oncogene 22:7359-68. 2003
    ..As the first of an expanding class of anticancer agents, lessons learned regarding the mechanism of rituximab action and resistance will be of increasing importance...
  36. ncbi Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities
    Lluis Colomo
    Hematopathology Section, Laboratory of Pathology, and Department of Hematology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Surg Pathol 28:736-47. 2004
    ..In conclusion, DLBCLs with plasmablastic differentiation are a heterogeneous group of neoplasms with different clinicopathological characteristics that may correspond to different entities...
  37. ncbi Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density
    Rinpei Niwa
    Tokyo Research Laboratories, Kyowa Hakko Kogyo, Co Ltd, 3 6 6 Asahi machi, Machida shi, Tokyo 194 8533, Japan
    Clin Cancer Res 11:2327-36. 2005
    ..In this report, we investigated the relationship between enhanced ADCC and antigen density on target cells using IgG1 antibodies with reduced fucose...
  38. ncbi Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
    D Shan
    Department of Biological Structure, University of Washington Medical Center, Seattle 98195 6043, USA
    Cancer Immunol Immunother 48:673-83. 2000
    ....
  39. ncbi 131I-tositumomab therapy as initial treatment for follicular lymphoma
    Mark S Kaminski
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109 0936, USA
    N Engl J Med 352:441-9. 2005
    ..Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse after chemotherapy or who have refractory follicular lymphoma, but it has not been tested in previously untreated patients...
  40. ncbi ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab
    Gunnar Tyden
    Department of Transplantation Surgery, Karolinksa University Hospital, Huddinge, Stockholm, Sweden
    Am J Transplant 5:145-8. 2005
    ....
  41. ncbi CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
    N Selenko
    Institute of Immunology and Department of Internal Medicine-I, University of Vienna Medical School, Austria
    Leukemia 15:1619-26. 2001
    ..These findings suggest that antibody treatment of tumor cells can, in addition to its direct cell damaging effects, under certain conditions, contribute to an induction of potentially protective cytotoxic T cell responses...
  42. ncbi Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism
    Rinpei Niwa
    Tokyo Research Laboratories, Kyowa Hakko Kogyo Co, Ltd, Tokyo, Japan
    Clin Cancer Res 10:6248-55. 2004
    ....
  43. ncbi ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC)
    Norio Chikatsu
    Department of Internal Medicine, Hitachi General Hospital, Hitachi, Ibaraki, USA
    Mod Pathol 16:828-32. 2003
    ..We consider that this case confirms the existence of ALK(+), CD30(-), CD20(-) large B-cell lymphomas proposed by Delsol et al. (16) and further provides relevant information regarding their clinicopathological features and cytogenetics...
  44. ncbi Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy
    Christopher J Sonnenday
    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Transplant 4:1315-22. 2004
    ..The use of rituximab, allowing avoidance of splenectomy, may further remove one of the significant disincentives to ABOi transplantation, and eliminate the risk of post-splenectomy infections...
  45. ncbi Pharmacodynamics of rituximab in kidney transplantation
    Helena Genberg
    Department of Transplantation Surgery, Karolinska University Hospital, Huddinge, Sweden
    Transplantation 84:S33-6. 2007
    ..In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B-cells in peripheral blood as well as within the kidney transplant...
  46. ncbi The radioisotope contributes significantly to the activity of radioimmunotherapy
    Thomas A Davis
    Stanford University, Stanford, California, USA
    Clin Cancer Res 10:7792-8. 2004
    ....
  47. ncbi Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials
    Gregory A Wiseman
    Nuclear Medicine, Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Nucl Med 44:465-74. 2003
    ..Dosimetry and pharmacokinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) were combined and assessed for correlations with toxicity data...
  48. ncbi Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer
    Khalid I Al-Shibli
    Department of Pathology, Nordland Central Hospital, Bodø, Norway
    Clin Cancer Res 14:5220-7. 2008
    ..However, the prognostic significance of tumor-infiltrating lymphocytes is controversial. The aim of this study is to elucidate the prognostic significance of epithelial and stromal lymphocyte infiltration in NSCLC...
  49. ncbi Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
    Mark S Cragg
    Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, General Hospital, Southampton, UK
    Blood 103:2738-43. 2004
    ..Thus, although complement is important for the action of rituximab and 1F5, this is not so for B1, which more likely functions through its ability to signal apoptosis...
  50. ncbi Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
    Taghi Manshouri
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Blood 101:2507-13. 2003
    ..01). The prognostic value of cCD20 was independent of Rai staging or hemoglobin level. Prospective evaluation is indicated to establish whether rituximab dosing should be adjusted according to cCD20 levels...
  51. ncbi Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice
    David J DiLillo
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 180:361-71. 2008
    ..Thereby, depleting mature and memory B cells does not have a dramatic negative effect on preexisting Ab levels...
  52. ncbi In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
    Olivier Manches
    Department of Research and Development, EFS Rhone Alpes, and Research Group on Lymphoma, Albert Bonniot Institute, La Tronche, France
    Blood 101:949-54. 2003
    ..Poor sensitivity to CDC in vitro might predict a poor clinical response, whereas high sensitivity to CDC would only indicate a likelihood of response to rituximab treatment...
  53. ncbi CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma
    C M Jubala
    Integrated Department of Immunology, AMC Cancer Center, University of Colorado Health Sciences Center, 1600 Pierce Street, 2 Diamond Research Building, Denver, CO 80214, USA
    Vet Pathol 42:468-76. 2005
    ..Thus, the use of CD20 as a therapeutic target will require the generation of specific antibodies against the extracellular domains of canine CD20...
  54. ncbi Isolation, tissue distribution, and chromosomal localization of a novel testis-specific human four-transmembrane gene related to CD20 and FcepsilonRI-beta
    M D Hulett
    Division of Immunology and Cell Biology, John Curtin School of Medical Research, ANU, P O Box 344, Canberra, ACT 2601, Australia
    Biochem Biophys Res Commun 280:374-9. 2001
    ..TETM4 is the first nonhematopoietic member of the CD20/FcepsilonRIbeta family, and like its hematopoietic-specific relatives, it may be involved in signal transduction as a component of a multimeric receptor complex...
  55. ncbi Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
    M S Kaminski
    Department of Internal Medicine, University of Michigan, Ann Arbor 48109 0724, USA
    J Clin Oncol 14:1974-81. 1996
    ....
  56. ncbi Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix
    Yulia Vugmeyster
    Bioanalytical Research and Development Department, Genentech, Inc, South San Francisco, California 94080, USA
    Cytometry A 52:101-9. 2003
    ..However, these differences are of crucial importance for interpretation of data from studies on new therapeutic agents aimed at B-cell depletion, such as anti-CD20 monoclonal antibodies...
  57. ncbi Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG
    Yulia Vugmeyster
    Bioanalytical Research and Development Department, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Int Immunopharmacol 4:1117-24. 2004
    ....
  58. ncbi The epitope recognized by rituximab
    Mascha Binder
    Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
    Blood 108:1975-8. 2006
    ..We conclude that rituximab binds a discontinuous epitope in CD20, comprised of (170)ANPS(173) and (182)YCYSI(185), with both strings brought in steric proximity by a disulfide bridge between C(167) and C(183)...
  59. ncbi Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients
    M Matignon
    Department of Nephrology and Transplantation, Henri Mondor Hospital, Creteil, France
    Transplant Proc 39:2565-7. 2007
    ..In these three cases of crossmatch-positive patients, rituximab failed to prevent antibody-mediated rejection. Others studies will be needed to determine the place of rituximab in these patients...
  60. ncbi Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells
    A Bräuninger
    Department of Pathology, University of Frankfurt, Germany
    Blood 93:2679-87. 1999
    ..Fluorescence in situ hybridization (FISH) points to a generalized polyploidy of the tumor cells...
  61. pmc Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis
    Maria Rehnberg
    Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Guldhedsgatan 10A, Gothenburg, Sweden
    Arthritis Res Ther 11:R123. 2009
    ..In the present study we evaluated changes in the B cell phenotype in peripheral blood and bone marrow (BM) of patients with rheumatoid arthritis (RA) following anti-CD20 treatment using rituximab...
  62. ncbi Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
    Qian Gong
    Department of Immunology, Genentech, South San Francisco, CA 94080, USA
    J Immunol 174:817-26. 2005
    ..These findings provide new insights into the mechanisms of immunotherapy and define new opportunities in the treatment of cancers and autoimmune diseases...
  63. ncbi The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice
    Yasuhito Hamaguchi
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 174:4389-99. 2005
    ..Thus, the majority of CD20(+) cells and B cell subsets within lymphoid tissues and the peritoneum could be depleted efficiently in vivo through Fc-dependent, but C-independent pathways during anti-CD20 immunotherapy...
  64. ncbi Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Cancer Biother Radiopharm 20:185-8. 2005
    ..This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with (90)Y ibritumomab tiuxetan treatment...
  65. ncbi History of antibody therapy for non-Hodgkin's lymphoma
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294 3300, USA
    Semin Oncol 30:1-5. 2003
    ..This article reviews important events in the development of mAb therapy and radioimmunotherapy for B-cell non-Hodgkin's lymphoma...
  66. ncbi Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys
    Carsten Schröder
    Department of Cardiothoracic Surgery, Vanderbilt University, Nashville, TN, USA
    Transpl Immunol 12:19-28. 2003
    ....
  67. ncbi Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene
    Kang Yu
    Department of Hematology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China
    Leuk Lymphoma 49:1368-73. 2008
    ..Our data indicate that CD3 and CD28 signalling can be delivered in one molecule, which is sufficient for complete T cell activation without exogenous B7/CD28 costimulation...
  68. pmc B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis
    Minoru Hasegawa
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Japan
    Am J Pathol 169:954-66. 2006
    ..Thereby, B-cell depletion during disease onset suppressed skin fibrosis, indicating that B cells contribute to the initiation of systemic sclerosis pathogenesis in tight-skin mice but are not required for disease maintenance...
  69. pmc Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
    Ronald P Taylor
    Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    Curr Opin Immunol 20:444-9. 2008
    ..The application of these mAbs, potentially in combination with immune effector modifying drugs, may successfully address the shortcomings of current anti-CD20 immunotherapy...
  70. ncbi Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment
    Y K Onno Teng
    Leiden University Medical Center, Leiden, The Netherlands
    Arthritis Rheum 56:3909-18. 2007
    ..The aim of this study was to investigate B cell depletion in different compartments (PB, bone marrow, and synovium) and determine predictive variables for responsiveness to rituximab therapy...
  71. ncbi Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases
    Kai U Chow
    University Hospital, Department of Internal Medicine III, Hematology and Oncology, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Haematologica 87:33-43. 2002
    ....
  72. ncbi Early phase of intestinal mantle cell lymphoma: a report of two cases associated with advanced colonic adenocarcinoma
    K Kanehira
    Department of Pathology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA
    Mod Pathol 14:811-7. 2001
    ..In both cases, immunohistochemistry (CD20+, CD5+, cyclin D1+, CD10-, and CD23-), and demonstration of clonal immunoglobulin heavy chain and bcl-1 gene rearrangements by PCR analysis confirmed the diagnosis of mantle cell lymphoma...
  73. ncbi Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment
    Petra Roll
    University of Wurzburg, Wurzburg, Germany
    Arthritis Rheum 58:1566-75. 2008
    ..The effects on B cell homeostasis after repeated treatments and the relationship of certain B cell subsets to clinical response or relapse are currently not known...
  74. ncbi Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells
    Salvatore De Vita
    University of Udine, Udine, Italy
    Arthritis Rheum 46:2029-33. 2002
    ..This study was undertaken to investigate the effects of B cell blockade in the treatment of refractory RA, and to evaluate the implications with regard to the role of B cells in the disease...
  75. ncbi Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    A J Davies
    Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, 45 Little Britain, St Bartholomew s Hospital, London EC1A 7BE, United Kingdom
    J Clin Oncol 22:1469-79. 2004
    ..An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma...
  76. ncbi Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy
    M Bokarewa
    Department of Rheumatology and Inflammation Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Scand J Immunol 66:476-83. 2007
    ..The treatment is well tolerated and may be used repeatedly in the same patient and potentially increase sensitivity to previously inefficient treatment modalities...
  77. ncbi Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis
    Petra Roll
    University of Wurzburg, Wurzburg, Germany
    Arthritis Rheum 54:2377-86. 2006
    ..The aim of this study was to delineate the regeneration profile of different B cell subsets in the peripheral blood after selective anti-CD20-mediated B cell depletion...
  78. ncbi Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy
    Samuel A Jacobs
    University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Clin Cancer Res 11:7146s-7150s. 2005
    ..We treated eight patients with 90Y ibritumomab tiuxetan who had prior autologous stem cell transplant, but met all other treatment criteria...
  79. ncbi Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
    ..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
  80. ncbi Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells
    M Kanzaki
    Department of Cell Biology, Gunma University, Maebashi, Japan
    J Biol Chem 270:13099-104. 1995
    ..These results indicate that CD20 expressed in Balb/c 3T3 cells functions as a constitutively active Ca(2+)-permeable cation channel and that expression of CD20 accelerates G1 progression in a Ca(2+)-dependent manner...
  81. ncbi B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses
    Hugo Mouquet
    INSERM, U905, Rouen, France
    J Invest Dermatol 128:2859-69. 2008
    ....
  82. ncbi Structural organization of the human MS4A gene cluster on Chromosome 11q12
    Y Liang
    Department of Immunology, Room 353 Jones Building, Research Drive, Duke University Medical Center, Durham, NC 27710, USA
    Immunogenetics 53:357-68. 2001
    ..Like CD20 and FcepsilonRIbeta, the 10 other human MS4A family members are likely to be components of oligomeric cell surface complexes involved in signal transduction in diverse cell lineages...
  83. ncbi CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma
    T van Meerten
    Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Neth J Med 67:251-9. 2009
    ..This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 monoclonal antibodies and explains new strategies to overcome resistance...
  84. ncbi From the bench to the bedside: ways to improve rituximab efficacy
    Guillaume Cartron
    UPRES EA Immuno Pharmaco Génétique des Anticorps thérapeutiques, UPRES EA, Universite Francois Rabelais, Tours, France
    Blood 104:2635-42. 2004
    ..A better understanding of how rituximab acts in vivo should make it possible to develop new and more effective therapeutic strategies...
  85. ncbi Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
    M J Leandro
    Centre for Rheumatology, University College London, London W1T 4JF, UK
    Rheumatology (Oxford) 46:29-36. 2007
    ..To assess the presence and phenotype of B-lineage cells in the bone marrow (BM) of rheumatoid arthritis (RA) patients after rituximab therapy...
  86. ncbi Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
    Mark S Cragg
    Tenovus Research Laboratory and Medical Oncology, Cancer Sciences Division, School of Medicine, General Hospital, Southampton, United Kingdom
    Blood 101:1045-52. 2003
    ....
  87. ncbi A cholesterol-dependent CD20 epitope detected by the FMC7 antibody
    M J Polyak
    Immunology Research Group, Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada
    Leukemia 17:1384-9. 2003
    ..FMC7 mAb binding thus appears to be a sensitive indicator of the level of plasma membrane cholesterol and reveals a conformational state of CD20 that is regulated by cholesterol...
  88. ncbi Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor
    K Ishibashi
    Department of Pharmacology, Jichi Medical School, Minamikawachi, Kawachi, 329 0498, Tochigi, Japan
    Gene 264:87-93. 2001
    ..The identification of this relatively large gene family in various tissues will allow the further elucidation of physiological significance of this gene family, that is currently unclear...
  89. ncbi Diffuse large B-cell lymphomas with plasmablastic differentiation
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Oncol Rep 7:357-63. 2005
    ..In this review, we discuss recently described clinicopathologic insights, case observations, and recently reported molecules involved in terminal B-cell or plasma cell differentiation and their possible roles in disease pathogenesis...
  90. ncbi Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis
    Tokihiko Sawada
    Tokyo Women s Medical University, Kidney Center, Department of Surgery, Tokyo, Japan
    Transplantation 74:1207-10. 2002
    ..In this case, the kidney transplantation was performed after the completion of a preconditioning regimen consisting of infusions of an anti-CD20 monoclonal antibody (rituximab), DFPP, and a splenectomy...
  91. ncbi Overcoming a positive crossmatch in living-donor kidney transplantation
    James M Gloor
    Department of Medicine, Division of Nephrology, Mayo Foundation and Clinic, 200 First St SW, Rochester, MN 55905, USA
    Am J Transplant 3:1017-23. 2003
    ..Longer follow-up will be needed, but the absence of anti-donor antibody and good early outcomes are encouraging...
  92. ncbi Mouse CD20 expression and function
    Junji Uchida
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    Int Immunol 16:119-29. 2004
    ..Thus, mouse and human CD20 share similar patterns of expression and function. These studies thereby provide an animal model for studying CD20 function in vivo and the molecular mechanisms that influence anti-CD20 immunotherapy...
  93. ncbi Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse
    Y Liang
    Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Genomics 72:119-27. 2001
    ..1 along with CD20, FcepsilonRIbeta, and HTm4. Thus, like CD20 and FcepsilonRIbeta, the other MS4A family members are likely to be components of oligomeric cell surface complexes that serve diverse signal transduction functions...
  94. ncbi Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis
    Yulia Vugmeyster
    Genentech, Inc, South San Francisco, California 94080, USA
    J Immunother 28:212-9. 2005
    ..After recovery, B-cell subsets were reconstituted to normal levels. Depletion of CD20-expressing cells and lymphoid follicular atrophy were the only treatment-related effects...
  95. ncbi An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab
    Adam D Kennedy
    Department of Biochemistry and Molecular Genetics, Center for Comparative Medicine, University of Virginia Health Sciences Center, Charlottesville 22908 0733, USA
    Blood 101:1071-9. 2003
    ....
  96. ncbi Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast
    D Tamiolakis
    Department of Cytology, Regional Hospital of Alexandroupolis, Democritus University of Thrace, Greece
    Eur J Gynaecol Oncol 23:433-6. 2002
    ..We conclude that MC tumor lymphocytic infiltrate demonstrates a mixed-T cytotoxic (CD8+) and B cell (CD20+)-immunophenotypic profile. This might in part explain the improved clinical outcome of the disease...
  97. ncbi Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study
    Peiguo G Chu
    Division of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA
    Am J Clin Pathol 126:534-44. 2006
    ..If negative, OCT.2 or BOB.1 may be useful. The newly identified B-lineage markers, OCT.2 and BOB.1, may be the most useful for the B-lineage determination of CD20- plasmablastic or primary effusion subtypes of DLBCL...
  98. pmc Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
    John M Pagel
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, the Univerisity of Washington, Seattle, WA 98109, USA
    Blood 108:328-36. 2006
    ..More than 90% of lymphomabearing mice could be cured with minimal toxicity using either reagent followed by 1200 muCi (44.4 MBq) 90Y-DOTA-biotin...
  99. ncbi Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas
    Richard I Fisher
    James P Wilmot Cancer Center, University of Rochester, NY, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
    ..Recent and ongoing studies are moving us closer towards that goal...
  100. ncbi Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation
    L Novoa-Takara
    Histopathology 47:333-4. 2005
  101. ncbi Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma
    Bridgette Collins-Burow
    Tulane University School of Medicine, Division of Hematology Medical Oncology, Tulane Cancer Center, 1430 Tulane Avenue, SL 78, New Orleans, LA 70112, USA
    Expert Rev Anticancer Ther 7:257-73. 2007
    ..In this article, we review the landmark trials that have impacted clinical practice in follicular and diffuse large B-cell lymphomas and the emerging data for use of rituximab as maintenance therapy in non-Hodgkin lymphoma...

Research Grants63

  1. ANTI-CD20 ANTIBODY THERAPY OF NHL-- MECHANISM OF ACTION
    David Maloney; Fiscal Year: 2002
    ..III. Determine the role of the mAb FC region in mediating anti- proliferative effects of anti-CD20 mAbs in xenografts of B cell NHL lines in NOD/SCID mice. ..
  2. Antibody-interferon fusion proteins for treatment of B-cell malignancies
    Sherie L Morrison; Fiscal Year: 2013
    ..B. Evaluate the in vivo efficacy of the fusion proteins against human lymphoma xenografts in combination with inhibitors of mTOR (temsirolimus) or PI3 kinase d (CAL-120). ..
  3. Alpha Radioimmunotherapy for Lymphoma Treatment
    BRENDA MARIE SANDMAIER; Fiscal Year: 2013
    ..We anticipate that the information from these studies will allow rapid translation of the optimized promising RIT strategy using 211At-anti-CD45 MAb into our clinical RIT HCT program for NHL. ..
  4. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2009
    ..abstract_text> ..
  5. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2010
    ..abstract_text> ..
  6. Identification of biomarkers of fatty acid intake
    Hannia Campos; Fiscal Year: 2002
    ..abstract_text> ..
  7. Nanobiotechnology for the Treatment of Mantle Cell Lymphoma
    Trudy Forte; Fiscal Year: 2009
    ..These studies will establish a novel approach with broad applicability, establishing targeted nanodisks as a platform that can be used with other forms of cancer, potentially decreasing the public burden associated with this disease. ..
  8. Radioimmunotherapy of CD20+ Lymphomas & CD45+Leukemias
    JOHN PAGEL; Fiscal Year: 2008
    ..abstract_text> ..
  9. Proapoptotic Therapy for B-cell Non Hodgkin's Lymphoma
    Ajay Gopal; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  10. B CELL SUPERANTIGENS AND IMMUNE REGULATION
    Gregg Silverman; Fiscal Year: 2008
    ..In addition, these studies will lead to a better understanding of the immunobiologic activities of a virulence factor from one of the most important causes of life-threatening infection in the US. ..
  11. Bispecific Antibody Pretargeting for Therapy
    ROBERT SHARKEY; Fiscal Year: 2009
    ..Anti-antibody responses will also be measured to the humanized bsMAb. This clinical trial will be conducted at the Fox Chase Cancer Center. ..
  12. OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMA
    Ajay Gopal; Fiscal Year: 2005
    ..We anticipate that these interventions will ultimately enhance the prognosis for patients with relapsed lymphoma by increasing the response and survival rates, while simultaneously minimizing toxicities. ..
  13. Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer
    ROBERT SHARKEY; Fiscal Year: 2008
    ..Overall, these studies will assist in establishing whether this type of pretargeting approach could have a role in the clinical management of pancreatic cancer. [unreadable] [unreadable] [unreadable]..
  14. Mechanisms to Induce Protective Natural Autoimmunity
    Gregg Silverman; Fiscal Year: 2004
    ..abstract_text> ..
  15. Improved Detection of Cancer Using Bi Specific Antibody
    ROBERT SHARKEY; Fiscal Year: 2003
    ....
  16. RAIT of Pancreatic Cancer with Humanized PAM4
    ROBERT SHARKEY; Fiscal Year: 2005
    ..The trial will be conducted at the Garden State Cancer Center and Johns Hopkins University School of Medicine. CMMI will be responsible for monitoring the study's progress. ..
  17. Arthritis Research Conference 2005
    Gregg Silverman; Fiscal Year: 2005
    ..abstract_text> ..
  18. RHEUMATIC DISEASES CORE CENTER
    Gregg Silverman; Fiscal Year: 2006
    ..An Administrative Core (PI-G.J. Silverman, Center Director) will provide overall direction and supervision to all Center programs through an Executive Committee, which will be assisted by an Outside Advisory Committee. ..
  19. Improved Detection of Cancer Using Bi Specific Antibody
    ROBERT SHARKEY; Fiscal Year: 2002
    ....
  20. Cell Death and Antibody-Mediated Protection from Autoimmunity
    GREGG JOSHUA SILVERMAN; Fiscal Year: 2010
    ....
  21. alpha4beta1 Intergrin Signaling In Immunity And Arthritis
    GREGG JOSHUA SILVERMAN; Fiscal Year: 2010
    ..Collectively, this work will provide insight into the role of the ct4-paxillin interaction in inflammation and immunity, and whether this interaction is a potential bona fide therapeutic target for arthritis. ..
  22. Arthritis Research Conference 2007
    Gregg Silverman; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  23. ACETABULAR BONE LOSS AFTER PROSTHETIC HIP ARTHROPLASTY
    R Looney; Fiscal Year: 2005
    ..In addition, DNA and serum samples from all subjects studied in this proposal will be banked. ..
  24. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007
    ..abstract_text> ..
  25. RADIOIMMUNOTHERAPY OF B CELL LYMPHOMA WITH ANTI CD74
    M Mattes; Fiscal Year: 2002
    ..This study may lead to the development of more effective radio-conjugates for the therapy of cancer and other diseases. Also, it will provide basic information about the toxic effects of intracellular (really lysosomal) radionuclides. ..
  26. MECHANISMS OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2009
    ..Such insights should be readily translatable to human autoimmune diseases. ..
  27. TECHNIQUES FOR CALCULATING TUMOR DOSIMETRY FROM IMAGING
    KENNETH KORAL; Fiscal Year: 2003
    ..Applications of the methods to other therapies and to imaging with other multi-gamma-emission radionuclides such as 111-In are also possible. ..
  28. BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
    Stephen Ansell; Fiscal Year: 2008
    ..abstract_text> ..
  29. MECHANISM OF AUTOREACTIVITY IN SLE
    Robert Eisenberg; Fiscal Year: 2001
    ..Is the pace of MRL/lpr disease dictated by events that occur after the early lymphocyte stage of ontogeny? 4. Does the genotype of the B cell control the lymphoproliferation of T cells? ..
  30. Radioimmunotherapy of Acute Leukemia
    Eneida Nemecek; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  31. Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma
    Oliver Press; Fiscal Year: 2007
    ..The preliminary results obtained to date suggest that this novel immunotherapy represents a safe, promising approach for patients with relapsed MCL. [unreadable] [unreadable] [unreadable]..
  32. HIV-1 Proviral DNA and Monocyte Phenotype in Relation to Neurocognitive Function
    Bruce T Shiramizu; Fiscal Year: 2010
    ..This resource-rich team is well-positioned to conduct this investigation into the pathogenesis of HAD. ..
  33. EFFECTOR MOLECULES IN DEMYELINATING DISEASE
    Anne Cross; Fiscal Year: 2001
    ..Since there now have been identified pharmaceutic agents which can inhibit the production of PN, our findings from these studies may indicate an area with therapeutic potential for MS. ..
  34. 11th & 12th Conference on Cancer Therapy with Antibodies and Immunoconjugates
    David Goldenberg; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  35. Immune control of SIVagm replication in vivo
    JOERN SCHMITZ; Fiscal Year: 2009
    ..3. Assess whether abolishing both cellular and humoral adaptive immune responses will affect the course of SIVagm infection of African green monkeys. ..
  36. Defining Biomarkers in Pediatric Renal Transplantation
    Minnie Sarwal; Fiscal Year: 2007
    ..The genomic and tissue microarray databases will be made publicly available for the academic community to facilitate future large-scale collaborative studies. [unreadable] [unreadable] [unreadable] [unreadable]..
  37. CD22 Regulation of B Lymphocyte Function and Survival
    Thomas Tedder; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  38. INTRACELLULAR TRAFFICKING OF IMMUNOTOXINS
    Oliver Press; Fiscal Year: 2003
    ....
  39. AUSTRALASIAN C0L0RECTAL CANCER FAMILY STUDY
    Jeremy Jass; Fiscal Year: 2002
    ..These characteristics include manageable yet sufficient size, ethnically diverse, highly localised, stable, and with families that are intact and large. ..
  40. CD8 LYMPHOCYTE RESPONSES IN SIV PATHOGENESIS
    JOERN SCHMITZ; Fiscal Year: 2004
    ..Determine the contribution of CD8+ lymphocytes to the loss of CD4+ Tcells following infection by SIVmac or the rapidly CD4+T cell-depleting virus SHIV-KB9. ..
  41. Activated Immune Parameters Associated with HIV & Aging
    Bruce Shiramizu; Fiscal Year: 2004
    ....
  42. DEFENSIN AND THE PATHOGENESIS OF ATHEROSCLEROSIS
    Douglas Cines; Fiscal Year: 2002
    ..Finally, the interaction between endogenous defensin and endogenous Lp(a) will be examined in a novel transgenic mouse than overexpresses both human defensin and human Lp(a). ..
  43. THE ROLE OF B CELLS IN EAE PATHOGENESIS
    Anne Cross; Fiscal Year: 2004
    ..Methods to alter in humans the number and function of B cells and Abs already exist, making our results potentially applicable to MS therapy. ..
  44. TRANSPLANT IMMUNOLOGY OF IL2 IFNY DOUBLE KNOCKOUT MICE
    Martin Zand; Fiscal Year: 2002
    ..In contrast, if the DKO mice are tolerant to islet allografts, we will determine the mechanism by adoptive transfer of tolerance inducing T lymphocyte subsets. ..
  45. PR3-ANCA Subsets and Disease Phenotype
    Ulrich Specks; Fiscal Year: 2005
    ..This study will provide new insights into the potential pathogenic role of PR3-ANCA that are not obtainable in any other way, and will constitute the most definitive study of these antibodies to date. ..
  46. Periodontal Assessment in RA Study (PARAS)
    Clifton Bingham; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  47. STRUCTURE/FUNCTION ANALYSIS OF THE UROKINASE RECEPTOR
    Douglas Cines; Fiscal Year: 2002
    ..abstract_text> ..
  48. B cell functional and signaling abnormalities in SLE
    Jennifer Anolik; Fiscal Year: 2006
    ..abstract_text> ..
  49. A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS
    DOROTHY CROSS; Fiscal Year: 2007
    ..Parks and Naismith, and PI will be able to focus 30% more time on investigator-initiated trials and mentoring junior colleagues. ..
  50. Mesenchymal Progenitors of Intragraft Fibroblasts
    GORDON WU; Fiscal Year: 2007
    ..Completion of this research project will have defined the FP of IF and determined the migratory mechanisms by which FP home to allografts during chronic rejection. ..
  51. INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
    Arnold Freedman; Fiscal Year: 2001
    ..Understanding the cell-cell interaction between BM stromal cells and pre-B ALL cells may provide future therapeutic strategies with which to modulate the growth of these leukemias. ..
  52. Chimeric Anti CD20 T Cell Receptors for Lymphoma Therapy
    Oliver Press; Fiscal Year: 2003
    ....
  53. ANNUAL MRI, MTR AND HMRSI IN HEALTHY CONTROLS AND PPMS
    Stephen Hauser; Fiscal Year: 2001
    ....
  54. Etanercept Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2003
    ..This study is a novel approach to treating FL, where targeting the microenvironment of the tumor may inhibit the growth and survival of the neoplastic cells. ..
  55. MS4A Family Members in Health and Disease
    Thomas Tedder; Fiscal Year: 2008
    ..abstract_text> ..
  56. CpG Plus Rituximab Therapy in Follicular Lymphoma
    Arnold Freedman; Fiscal Year: 2005
    ..This study is a novel approach to treating FL, where augmenting antigen presentation and effector cells may lead to enhanced cytotoxic effects of rituximab and induce anti-tumor immunity. ..
  57. CD83 Regulation of Lymphocyte Development and Function
    Thomas Tedder; Fiscal Year: 2007
    ..an important regulatory checkpoint for helper T cell development, understanding its function may provide mechanisms for modulating humoral immunity and for the treatment of immunodeficiency, autoimmunity and malignancies ..
  58. REGULATION OF LEUKOCYTE RECIRCULATION
    Thomas Tedder; Fiscal Year: 2001
    ....
  59. CpG ODN as an Immune Adjuvant
    George Weiner; Fiscal Year: 2006
    ..The results of these studies will allow for the rational design of the next generation of moAb-based approaches to the therapy of B-cell and other malignancies. ..
  60. Cordyceps Sinensis Evaluation in IgA Nephropathy Model
    Abdalla Rifai; Fiscal Year: 2005
    ..These studies will generate novel insights into molecular mechanisms underlying pathogenesis of IgA nephropathy and predict outcomes from safe traditional alternative medicine for prevention of renal failure. ..